98 results on '"Rönnelid, Johan"'
Search Results
2. In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
3. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis
4. Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants
5. The EuroMyositis registry: an international collaborative tool to facilitate myositis research
6. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
7. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up
8. 07.17 The mutated rna splicing protein hnrnp-a3 is a novel autoantigen in systemic rheumatic diseases a link to warburg effect in ra
9. 05.09 The role of the european consensus finding study group (ecfsg) in characterising new tentative reference standards for autoantibody measurement
10. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus
11. The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? Antibodies against uncitrullinated peptides seem to occur prior to the antibodies to the corresponding citrullinated peptides
12. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
13. Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis
14. Correspondence on ‘Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities’
15. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset
16. Response to: ‘Comment on: standardisation of myositis-specific antibodies: where are we today?’ by Infantino et al
17. A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation
18. Response to: ‘Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?’ by Cavazzana et al
19. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies
20. Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis
21. Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?
22. Response to: ‘Detection of myositis-specific antibodies: additional notes’ by Infantino et al
23. Response to: ‘Detection of myositis-specific antibodies’ by Vulstekeet al
24. Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants
25. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
26. Antibodies against collagen type II are not a general marker of acute arthritis onset
27. Correspondence on 'Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities'.
28. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation
29. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus
30. A1.11 Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in ra patients with anti-collagen antibodies
31. A1.1 Characterisation of lung inflammation and identification of shared citrullinated targets in the lungs and joints of early rheumatoid arthritis
32. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies
33. A5.24 Neutrophil Granulocytes Respond to Surface-Bound Immune Complexes Containing Anti-Type II Collagen Antibodies from RA Patients
34. A10.15 IgA Rheumatoid Factor is more Predominant than anti-CCP in Sudanese Rheumatoid Arthritis Patients, whereas IgG RF is a Strong Prognostic Marker and Associated with Early Onset
35. A6.10 High Disease Activity and Erosion Rate in Sudanese Rheumatoid Arthritis Patients
36. A5.12 Disappearance and Reappearance of IgG, IgA and IgM Autoantibody Isotypes and Immune Complexes in Rituximab-Treated SLE Patients
37. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis
38. Antibodies against native collagen and citrullinated proteins precede the development of rheumatoid arthritis with a consecutive pattern
39. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden
40. Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis
41. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis
42. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.
43. Response to: 'Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?' by Cavazzana .
44. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden.
45. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke.
46. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis.
47. Response to: 'Comment on: standardisation of myositis-specific antibodies: where are we today?' by Infantino .
48. Antibodies against collagen type II are not a general marker of acute arthritis onset.
49. Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?
50. Response to: 'Detection of myositis-specific antibodies: additional notes' by Infantino .
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.